Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Aug 20, 2025

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Liposomal amphotericin B-the future.

M Hoenigl^1,2,3, R Lewis⁴, F L van de Veerdonk⁵

¹Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

The Journal of Antimicrobial Chemotherapy

|November 25, 2022

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Risk factors for acquisition and severity of Acanthamoeba and Fusarium keratitis in contact lens users-A case-control and clinical-epidemiological study, 2009-2020.

Acta ophthalmologica·2026

Same author

The black aspergilli (<i>Aspergillus niger</i> complex) and their role in human, animal, and plant diseases.

Clinical microbiology reviews·2026

Same author

Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML.

Antimicrobial agents and chemotherapy·2026

Same author

Rising Antifungal Resistance in Candidozyma auris: Signals, Gaps, and the Path Forward.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Global Review on <i>Naegleria fowleri</i> Cases: Contemporary Epidemiology, Diagnosis, Treatment and Outcomes.

Infectious disease reports·2026

Same author

Genotype-Phenotype Relationships in Azole-Resistant <i>Aspergillus</i>: Two Sides of the Same Coin.

Journal of fungi (Basel, Switzerland)·2026

Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026

Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026

Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026

Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026

Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026

Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026

See all related articles

This summary is machine-generated.

Invasive fungal infections are rising in immunocompromised patients, especially in ICUs, due to factors like viral pneumonia and new cancer therapies. Early diagnosis and broad-spectrum antifungals like liposomal amphotericin B are crucial for survival.

Area of Science:

Medical Mycology
Infectious Diseases
Critical Care Medicine

Background:

Increasing prevalence of invasive fungal infections (IFIs) in immunocompromised individuals.
Emergence of IFIs in intensive care units (ICUs) beyond traditional risk groups.
Association of severe viral pneumonia (e.g., influenza, COVID-19) with invasive pulmonary aspergillosis.

Purpose of the Study:

To highlight the evolving landscape of invasive fungal infections.
To discuss new risk factors and challenges in diagnosis and treatment.
To emphasize the importance of early detection and effective antifungal strategies.

Main Methods:

Review of current medical literature and clinical observations.
Analysis of trends in fungal infection epidemiology.

More Related Videos

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Published on: March 3, 2020

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Related Experiment Videos

Last Updated: Aug 20, 2025

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Published on: March 3, 2020

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Assessment of emerging risk factors and treatment challenges.

Main Results:

IFIs are increasingly common in ICUs, linked to viral pneumonias and targeted cancer therapies (e.g., ibrutinib).
Drug-drug interactions between antifungals and kinase inhibitors pose a risk.
Rising incidence of rare fungal infections and growing azole resistance necessitate surveillance.

Conclusions:

Early diagnosis and appropriate treatment are critical for survival in patients with IFIs.
Broad-spectrum antifungal agents are essential for managing future challenges.
Liposomal amphotericin B remains a vital therapeutic option due to its efficacy and safety profile.